Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Perspective on malignant pleural mesothelioma diagnosis and treatment.

Literature DB >> 27127773

Perspective on malignant pleural mesothelioma diagnosis and treatment.

Ori Wald¹, David J Sugarbaker¹.

Abstract

Entities: Disease

Year: 2016 PMID： 27127773 PMCID： PMC4828731 DOI： 10.21037/atm.2016.03.17

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

16 in total

1. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: P Baas; D Fennell; K M Kerr; P E Van Schil; R L Haas; S Peters
Journal: Ann Oncol Date: 2015-07-28 Impact factor: 32.976

2. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

Authors: D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer
Journal: J Thorac Cardiovasc Surg Date: 1999-01 Impact factor: 5.209

3. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass.

Authors: Valerie Rusch; Elizabeth H Baldini; Raphael Bueno; Marc De Perrot; Raja Flores; Seiki Hasegawa; Walter Klepetko; Lee Krug; Loïc Lang-Lazdunski; Harvey Pass; Walter Weder; David J Sugarbaker
Journal: J Thorac Cardiovasc Surg Date: 2013-02-14 Impact factor: 5.209

4. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.

Authors: P E Van Schil; P Baas; R Gaafar; A P Maat; M Van de Pol; B Hasan; H M Klomp; A M Abdelrahman; J Welch; J P van Meerbeeck
Journal: Eur Respir J Date: 2010-06-04 Impact factor: 16.671

5. Survival after conservative (palliative) management of pleural malignant mesothelioma.

Authors: N Merritt; C J Blewett; J D Miller; W F Bennett; J E Young; J D Urschel
Journal: J Surg Oncol Date: 2001-11 Impact factor: 3.454

6. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.

Authors: Daniel R Gomez; David S Hong; Pamela K Allen; James S Welsh; Reza J Mehran; Anne S Tsao; Zhongxing Liao; Stephen D Bilton; Ritsuko Komaki; David C Rice
Journal: J Thorac Oncol Date: 2013-02 Impact factor: 15.609

7. Initial analysis of the international association for the study of lung cancer mesothelioma database.

Authors: Valerie W Rusch; Dorothy Giroux; Catherine Kennedy; Enrico Ruffini; Ayten K Cangir; David Rice; Harvey Pass; Hisao Asamura; David Waller; John Edwards; Walter Weder; Hans Hoffmann; Jan P van Meerbeeck
Journal: J Thorac Oncol Date: 2012-11 Impact factor: 15.609

8. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.

Authors: Marc de Perrot; Ronald Feld; B C John Cho; Andrea Bezjak; Masaki Anraku; Ronald Burkes; Heidi Roberts; Ming S Tsao; Natasha Leighl; Shaf Keshavjee; Michael R Johnston
Journal: J Clin Oncol Date: 2009-02-17 Impact factor: 44.544

9. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

Authors: Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang
Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544

10. Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).

Authors: Seiki Hasegawa; Morihito Okada; Fumihiro Tanaka; Takeharu Yamanaka; Toshinori Soejima; Norihiko Kamikonya; Tohru Tsujimura; Kazuya Fukuoka; Kohei Yokoi; Takashi Nakano
Journal: Int J Clin Oncol Date: 2015-11-17 Impact factor: 3.402

5 in total

Perspective on malignant pleural mesothelioma diagnosis and treatment.

1. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

2. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

3. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass.

4. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.

5. Survival after conservative (palliative) management of pleural malignant mesothelioma.

6. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.

7. Initial analysis of the international association for the study of lung cancer mesothelioma database.

8. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.

9. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

10. Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).

Review 1. Overview of treatment related complications in malignant pleural mesothelioma.

Review 2. Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma.

Review 3. Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.

Review 4. New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.

5. Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma.